Market Cap
$278.0B
NVS
NOVARTIS AG
$140.87 ▼ -0.13%
Prev close $141.05Market cap$278.0B
ConsensusHold
12-mo target$156.29 (+10.9%)
▲ Neutral
Analyst conviction 5/10
High Impact Filing (7/10)23 New Institutional Positions21 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on NVS right now — valuation, ownership and activity at a glance.
Cap Size
Mega Cap
Analyst Consensus
Hold (47%)
Inst. Holders
50 funds
Inst. Value
$16.3B
Inst. Activity
23 buys / 21 sells
Social Sentiment
50° Neutral
SEC Reports
9
Price chart 30d -13.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 clinical_trial_readout
Sep 4, 2026 SEC T-90d Trial Readout: everolimus (Phase 3)
Trial: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen, an investigational antisense oligonucleotide ta
6-K — Impact 6/10
Novartis announced positive Phase III topline results for remibrutinib in relapsing multiple sclerosis (RMS). The REMODE
6-K — Impact 7/10
Aug 19, 2026 Event
Aug 6, 2026 SEC Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34
Class II: Failed Dissolution Specifications
A federal magistrate judge denied without prejudice Novartis's generic-drug defendants' motion to compel discovery into
COURT-RULING — Impact 2/10
Aug 5, 2026 Event
HSR Early Termination: Novartis AG; Myricx Pharma Limited
The FTC granted early termination of the HSR Act waiting period for a transaction involving Novartis
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — TRIM
2,980,168 shares ($467.1M)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO — ADD
2,264,447 shares ($356.9M)
Analyst ratings buy % -6.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
47% rate it Buy or better · 34 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | UPGRADE | Hold | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 10 | 14 | 4 | 0 | 47% | |
| Aug 1, 2026 | 6 | 10 | 14 | 4 | 0 | 47% | |
| Jul 1, 2026 | 6 | 11 | 14 | 3 | 0 | 50% | |
| Jun 1, 2026 | 6 | 11 | 14 | 3 | 0 | 50% | |
| May 1, 2026 | 6 | 11 | 14 | 3 | 0 | 50% | |
| Apr 1, 2026 | 6 | 10 | 14 | 4 | 0 | 47% | |
| Mar 1, 2026 | 6 | 10 | 14 | 4 | 0 | 47% | |
| Feb 1, 2026 | 7 | 10 | 13 | 4 | 0 | 50% |
Price targets
Where 11 covering analysts think NVS trades over the next 12 months.
$156.29 +10.9% upside Buy
Current$140.87 Low$130.00 Median$160.15 High$185.00 11 analysts
$130.00$185.00
Analyst rating Hold· 2.6/5 as of Oct 2, 2026
Social media sentiment mood -20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 1 bullish, 4 bearish, 0 mixed, 4 neutral · avg impact 4.4/10.
BEARISH6-K6/10
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen, an investigational antisens
Sep 4, 2026
BULLISH6-K7/10
Novartis announced positive Phase III topline results for remibrutinib in relapsing multiple scleros
Sep 1, 2026
NEUTRALCOURT-RULING2/10
A federal magistrate judge denied without prejudice Novartis's generic-drug defendants' motion to co
Aug 6, 2026
NEUTRALCOURT-RULING1/10
A federal district court in the Northern District of California issued a routine order granting pro
Jul 29, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
Iptacopan in Patients With ANCA Associated Vasculitis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Oct 1, 2026
Clinical Trial
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Oct 1, 2026
clinical_trial_readout
T-90d Trial Readout: everolimus (Phase 3)
Trial: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-
Oct 1, 2026
clinical_trial_readout
T-90d Trial Readout: Iptacopan (Phase 2)
Trial: Iptacopan in Patients With ANCA Associated Vasculitis Sponsor: Novartis Pharmaceuticals Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING Conditio
Sep 28, 2026
Clinical Trial
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.23 | $2.20–$2.26 | -1.0% | -0.1% | 1↑ 0↓ | $14.6B | 3 |
| Next Q | $2.16 | $2.01–$2.27 | 6.3% | +2.6% | 0↑ 1↓ | $14.9B | 3 |
| Current FY | $8.85 | $8.62–$9.04 | -1.5% | +0.5% | 0↑ 1↓ | $57.7B | 9 |
| Next FY | $9.84 | $9.30–$10.75 | 11.2% | +0.3% | 1↑ 0↓ | $61.4B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.227 | — |
| 7d ago | $2.230 | -0.003 |
| 30d ago | $2.230 | -0.003 |
| 60d ago | $2.230 | -0.003 |
| 90d ago | $2.171 | +0.055 |
Institutional ownership
Which big funds own NVS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $16.3B total value (103,713,783 shares) as of 2026-Q2. Top holders: Fisher, MORGAN, DIMENSIONAL. Net buying activity: 23 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Fisher Asset Management, LLC | 15,523,378 | $2.4B | 15.0% | ADD +86.0% |
| MORGAN STANLEY | 8,726,827 | $1.4B | 8.4% | — |
| DIMENSIONAL FUND ADVISORS LP | 8,117,586 | $1.3B | 7.8% | — |
| PRIMECAP MANAGEMENT CO/CA/ | 6,592,124 | $1.0B | 6.4% | — |
| LOOMIS SAYLES & CO L P | 5,239,309 | $821.1M | 5.1% | — |
| BANK OF AMERICA CORP /DE/ | 4,909,938 | $769.5M | 4.7% | — |
| FRANKLIN RESOURCES INC | 3,251,281 | $509.5M | 3.1% | — |
| BlackRock, Inc. | 3,047,988 | $477.7M | 2.9% | — |
| GOLDMAN SACHS GROUP INC | 2,980,168 | $467.1M | 2.9% | TRIM -54.3% |
| NORTHERN TRUST CORP | 2,792,745 | $437.7M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | TRIM | 6,525,771 | 2,980,168 | -54.3% | $467.1M |
| JPMORGAN CHASE & CO | ADD | 1,804,676 | 2,264,447 | +25.5% | $356.9M |
| WCM INVESTMENT MANAGEMENT, LLC | ADD | 1,463,180 | 1,904,349 | +30.2% | $300.1M |
| UBS Group AG | TRIM | 1,793,153 | 1,184,422 | -33.9% | $185.6M |
| Holocene Advisors, LP | NEW | — | 1,037,332 | — | $162.6M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,111,833 | 788,033 | -29.1% | $123.5M |
| DODGE & COX | NEAR_EXIT | 6,967,383 | 759,373 | -89.1% | $119.0M |
| MILLENNIUM MANAGEMENT LLC | NEW | — | 758,029 | — | $118.8M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 505,440 | 740,532 | +46.5% | $116.1M |
| VAN ECK ASSOCIATES CORP | TRIM | 891,803 | 633,523 | -29.0% | $99.3M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NVS.
Shares short
5,195,725
Settlement Sep 15, 2026
Change vs prior
-7.6%
Semi-monthly cycle
Days to cover
1.5
At avg daily volume
Of shares outstanding
≈0.3%
Estimate — not % of float
All NVS filing & press-release reports (9)
- 6-K reportSep 4, 2026
- 6-K reportSep 1, 2026
- COURT-RULING reportAug 6, 2026
- COURT-RULING reportJul 29, 2026
- 6-K reportJul 21, 2026
- COURT-RULING reportJul 1, 2026
- COURT-RULING reportMay 4, 2026
- COURT-RULING reportApr 21, 2026
- COURT-RULING reportMar 30, 2026